KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Treasury Shares (2018 - 2024)

Historic Treasury Shares for Vir Biotechnology (VIR) over the last 7 years, with Q4 2024 value amounting to $5.0 million.

  • Vir Biotechnology's Treasury Shares rose 366.53% to $5.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $5.0 million, marking a year-over-year increase of 366.53%. This contributed to the annual value of $5.0 million for FY2024, which is 366.53% up from last year.
  • Per Vir Biotechnology's latest filing, its Treasury Shares stood at $5.0 million for Q4 2024, which was up 366.53% from $4.8 million recorded in Q4 2023.
  • Vir Biotechnology's Treasury Shares' 5-year high stood at $5.0 million during Q4 2024, with a 5-year trough of $89261.0 in Q4 2020.
  • In the last 5 years, Vir Biotechnology's Treasury Shares had a median value of $1.2 million in 2021 and averaged $1.9 million.
  • As far as peak fluctuations go, Vir Biotechnology's Treasury Shares crashed by 8945.91% in 2020, and later soared by 132428.83% in 2021.
  • Quarter analysis of 5 years shows Vir Biotechnology's Treasury Shares stood at $89261.0 in 2020, then surged by 1324.29% to $1.3 million in 2021, then surged by 109.84% to $2.7 million in 2022, then soared by 80.11% to $4.8 million in 2023, then grew by 3.67% to $5.0 million in 2024.
  • Its Treasury Shares was $5.0 million in Q4 2024, compared to $4.8 million in Q4 2023 and $2.7 million in Q4 2022.